Qdenga: Crunch Time For First Product In Parallel Review Route For EU And Non-EU Markets

Takeda could soon learn whether the European Medicines Agency will recommend in favor of approving its dengue vaccine, which was reviewed under a new evaluation route that simultaneously targets EU and non-EU countries.

Mosquito
Takeda says dengue was one of the WHO’s top 10 threats to global health in 2019 • Source: Shutterstock: frank60

Qdenga, the dengue vaccine from Takeda Pharmaceutical, which was the first product to test drive the European Medicines Agency’s parallel review route for EU and non-EU markets, is up for opinion by the agency on whether it should be approved.

The EMA is due to adopt a decision on the vaccine this week, around two and a half years after...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography